The Technical Analyst
Electromedical [EMED]
Exchange: OTC Sector: Healthcare Industry: Medical Devices
Electromedical Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $0.0005
America/New_York / 3 mai 2024 @ 15:20
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 0.254 mill |
| EPS: | -0.0200 |
| P/E: | -0.0200 |
| Earnings Date: | N/A |
| SharesOutstanding: | 507.29 mill |
| Avg Daily Volume: | 1.609 mill |
| RATING 2024-05-03 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0200 | sector: PE 29.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -0.0200 | industry: PE 38.34 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0005 - 0.0005 ( +/- 0.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-02-06 | Hymers Iii R. Leslie | Buy | 35 000 000 | Common Stock |
| 2022-12-20 | Hymers Iii R. Leslie | Sell | 0 | Common Stock |
| 2022-11-02 | Benson Lee | Buy | 1 658 999 | Common Stock |
| 2022-09-29 | Benson Lee | Buy | 0 | Common |
| 2021-07-08 | Steinberg Donald J | Sell | 57 417 | Common |
| INSIDER POWER |
|---|
| 100.00 |
| Last 46 transactions |
| Buy: 37 758 999 | Sell: 590 000 |
Forecast:
16:00 - $0.0005
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0005 (0.00% ) |
| Volume | 1.211 mill |
| Avg. Vol. | 1.609 mill |
| % of Avg. Vol | 75.26 % |
| Signal 1: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EMED
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EMED
Electromedical Technologies, Inc., a bioelectronics manufacturing and marketing company, provides medical devices for pain management in the United States. It offers WellnessPro Plus, a bioelectronics therapy prescription device that is used by consumers and health care professionals to relieve chronic and acute pain. The company was founded in 2002 and is headquartered in Scottsdale, Arizona.
Latest Press Releases
2021-09-30 06:00:00 - Press Release
Electromedical Technologies Receives Key Medical Device Certification
Scottsdale, ariz., sept. 30, 2021 /prnewswire/ -- electromedical technologies, inc. (otcqb: emed) (the "company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that it has passed the iso 13485:2016 recertification audit for medical device and quality management systems.
2021-08-19 11:55:00 - Press Release
Electromedical Technologies Clarifies Comparative Six-month Highlights Reported In August 18, 2021 Press Release
Scottsdale, ariz., aug. 19, 2021 /prnewswire/ -- electromedical technologies, inc. (otcqb: emed) (the "company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, clarifies and corrects its previously published press release disclosing comparative results from the six months ended june 30, 2021 versus june 30, 2020.
2021-08-18 07:56:00 - Press Release
Electromedical Technologies Reports Comparative 48% Revenue Growth For June 2021 Quarter
Scottsdale, ariz., aug. 18, 2021 /prnewswire/ -- electromedical technologies, inc. (otcqb: emed) (the "company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that it recorded strong results for the second quarter of 2021, ending june 30, as compared to the same period in 2020.
2021-07-29 06:00:00 - Press Release
Electromedical Technologies And Nazarbayev University To Commence Landmark Alzheimer's Disease Research Program
•the stage i research program now includes development of targeted alzheimer's disease therapy using bioelectronics •experienced neuroscientist dr. sholpan askarova to lead neuromodulation research program •key objective is identification of electrical frequencies with a neuroprotection potency •novel approach could emerge as alternative alzheimer's disease therapy to current, ineffective pharmaceuticals •global therapy market is huge, estimated to reach $13.3 billion in 2023 •the stage i research program now includes development of targeted alzheimer's disease therapy using bioelectronics •experienced neuroscientist dr. sholpan askarova to lead neuromodulation research program •key objective is identification of electrical frequencies with a neuroprotection potency •novel approach could emerge as alternative alzheimer's disease therapy to current, ineffective pharmaceuticals •global therapy market is huge, estimated to reach $13...
2021-06-10 12:08:00 - Press Release
Electromedical Technologies Flagship Device To Be Introduced At National Chiropractic Expo
- emed director kathy strand r.n. hosting booth at parker seminars expo in orlando june 11th-13th - parker seminars hosts semi-annual expo and seminars for chiropractors and their assistants - presence at the expo could build awareness and on-board new practitioners and sales reps --the orlando event features u.s. surgeon general as keynote speaker scottsdale, ariz.
Latest News
2021-09-30 06:00:00 - PRNewsWire
Electromedical Technologies Receives Key Medical Device Certification
SCOTTSDALE, Ariz., Sept. 30, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that it has passed the ISO 13485:2016 recertification audit for Medical Device and Quality Management Systems.
2021-08-19 11:55:00 - PRNewsWire
Electromedical Technologies Clarifies Comparative Six-Month Highlights Reported in August 18, 2021 Press Release
SCOTTSDALE, Ariz., Aug. 19, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, clarifies and corrects its previously published press release disclosing comparative results from the six months ended June 30, 2021 versus June 30, 2020.
2021-08-18 07:56:00 - PRNewsWire
Electromedical Technologies Reports Comparative 48% Revenue Growth for June 2021 Quarter
SCOTTSDALE, Ariz., Aug. 18, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and production of bioelectronic devices designed to relieve chronic, intractable and acute pains by using frequencies and electro-modulation, is pleased to announce that it recorded strong results for the second quarter of 2021, ending June 30, as compared to the same period in 2020.
2021-07-29 06:00:00 - GlobeNewsWire
Electromedical Technologies and Nazarbayev University to Commence Landmark Alzheimer's Disease Research Program
•The Stage I research program now includes development of targeted Alzheimer's Disease therapy using bioelectronics •Experienced neuroscientist Dr. Sholpan Askarova to lead neuromodulation research program •Key objective is identification of electrical frequencies with a neuroprotection potency •Novel approach could emerge as alternative Alzheimer's Disease therapy to current, ineffective pharmaceuticals •Global therapy market is huge, estimated to reach $13.3 billion in 2023 •The Stage I research program now includes development of targeted Alzheimer's Disease therapy using bioelectronics •Experienced neuroscientist Dr. Sholpan Askarova to lead neuromodulation research program •Key objective is identification of electrical frequencies with a neuroprotection potency •Novel approach could emerge as alternative Alzheimer's Disease therapy to current, ineffective pharmaceuticals •Global therapy market is huge, estimated to reach $13...
2021-06-10 12:08:00 - PRNewsWire
Electromedical Technologies Flagship Device to Be Introduced at National Chiropractic Expo
- EMED Director Kathy Strand R.N. hosting booth at Parker Seminars Expo in Orlando June 11th-13th - Parker Seminars hosts semi-annual expo and seminars for chiropractors and their assistants - Presence at the expo could build awareness and on-board new practitioners and sales reps --The Orlando event features U.S. Surgeon General as Keynote Speaker SCOTTSDALE, Ariz.
2021-06-03 06:00:00 - PRNewsWire
Electromedical Technologies and Nazarbayev University Complete Agreement to Expand Promising Joint Research Programs
- Studies could lead to development of next-generation targeted devices to effectively treat chronic pain - Stage I research programs designed to study how electro-modulation communicates to cells - Program objective to d ecipher impacts of alternating electrical fields on cell signaling and generating cellular response - Leveraging the executed agreement EMED and Nazarbayev plan to begin the IDE process with the FDA SCOTTSDALE, Ariz., June 3, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+®, is pleased to announce that the Company recently completed an agreement with Nazarbayev University to expand its Stage I collaborative research programs.
2021-05-25 08:33:00 - PRNewsWire
Electromedical Technologies' New Weekly Marketing Series Launches This Week
SCOTTSDALE, Ariz., May 25, 2021 /PRNewswire/ -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro Plus®, is pleased to announce that following a successful Facebook Live WellnessPro Plus® testimonial event with a noted chiropractor, the Company is launching two weekly marketing events, beginning Wednesday, May 26, 2021.
2021-05-19 06:00:00 - GlobeNewsWire
Electromedical Technologies Announces Upcoming Facebook Live Event with Noted Chiropractor
- Event with Dr. Jeff Harper to highlight the benefits of the WellnessProPlus® for chronic pain sufferers - Facebook Live Event schedule for TODAY, May 19, 2021 at 2:20 PM CST (12:20pm PST/3:20pm EST) - Online meeting is the first in a series to foster broad awareness and utilization of EMED's devices
2021-04-20 10:32:00 - GlobeNewsWire
Electromedical Technologies Enters Phase 2 of Prototype development on WellnessPro POD™
2021-04-13 06:00:00 - GlobeNewsWire
Electromedical Technologies, Inc. Featured on The Big Biz Radio Show
CEO Matthew Wolfson recently Interviewed three times by Popular Media Host Bob “Sully” Sullivan on the Big Biz Radio Show CEO Matthew Wolfson recently Interviewed three times by Popular Media Host Bob “Sully” Sullivan on the Big Biz Radio Show